Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.
You may also be interested in...
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
Omeros' Epic IPO Voyage Could be Delayed by a Former CFO's Lawsuit
The Seattle biotech navigates the recession and resuscitates its IPO, but its former CFO is now a whistleblower and has erected a legal hurdle.